Dakovir-C (daclatasvir) is an inhibitor of HCV nonstructural protein 5A (NS5A). Daclatasvir is an inhibitor of NS5A, a nonstructural protein encoded by HCV. Daclatasvir binds to the N-terminus of NS5A and inhibits both viral RNA replication and virion assembly. It is indicated for use with sofosbuvir for the treatment of chronic HCV genotype 3 infection.
It is EASL (Europen Association for the Study of Liver), APASL (Asia Pacific Association for the Study of Liver) recommended Pangenotypic treatment option for Hepatitis C with other Direct Acting Antivirals.
Dakovir-C is a PANGENOTYPIC, EFFECTIVE AND ECONOMIC treatment for HCV and numerous benefits:
- Highly effective in all genotype of HCV with other DAAs
- Most economic option to treat hepatitis C
- Shorter treatment period than other antiviral therapy
- Effective in HCV patient with cirrhosis